Dice therapeutics 10q
WebDICE Therapeutics. 4,014 followers. 7mo. We are pleased to announce the completion of enrollment in our Phase 1 clinical trial of DC-806. DC-806 is an orally-available, small molecule antagonist ... WebDICE Therapeutics, Inc. (Filer) CIK: 0001645569 (see all company filings) IRS No.: 472286244 State of Incorp.:DE Fiscal Year End: 1231 Type: S-1MEF Act: 33 ...
Dice therapeutics 10q
Did you know?
WebDICE Therapeutics started at outperform with $60 stock price target at Evercore ISI. Oct. 11, 2024 at 6:16 a.m. ET by Tomi Kilgore. WebOct 25, 2024 · DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. ... (SEC) pursuant to Rule 424(b)(4) on September 16, 2024, and our other SEC filings. Accordingly, readers are ...
WebAug 11, 2024 · Inside Dice Therapeutics, Inc.'s 10-Q Quarterly Report: Financial - Expense Highlight. The increase of $5.1 million and $9.1 million for the three and six months ended June 30, 2024, respectively, was primarily due to increases in personnel-related expenses of $3.0 million and $4.5 million, respectively, resulting from an increase in headcount ... WebNov 9, 2024 · Dice Therapeutics, Inc. (DICE) SEC Filing 10-Q Quarterly Report for the period ending Friday, September 30, 2024
WebDice Therapeutics (DICE) Receives a Buy from SVB Securities March 20, 2024TipRanks. Analysts’ Top Healthcare Picks: Paratek Pharmaceuticals (PRTK), Indaptus … WebApr 1, 2024 · DICE Therapeutics Stock Performance. Shares of DICE opened at $28.67 on Friday. DICE Therapeutics has a 52-week low of $12.64 and a 52-week high of $45.99. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -13.40 and a beta of 0.71. The business's fifty day moving average is $29.47 and its 200-day moving average is …
WebMar 26, 2024 · DICE stock opened at $27.21 on Friday. The company's fifty day simple moving average is $29.55 and its 200 day simple moving average is $29.74. DICE Therapeutics has a 12-month low of $12.64 and a 12-month high of $45.99. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -12.71 and a beta of 0.71.
WebSep 11, 2024 · Summary. Dice Therapeutics has filed to raise $160 million in an IPO of its common stock. The firm is developing treatments for immune system diseases and other serious health conditions. crystaldiskinfo open sourceWebNov 9, 2024 · The Investor Relations website contains information about DICE Therapeutics's business for stockholders, potential investors, and financial analysts. crystaldiskinfo official siteWebApr 6, 2024 · DICE Therapeutics, Inc. (DICE) - DEFA14A - Additional Proxy Soliciting Materials (definitive) SEC Filings Tue, Apr. 26, 2024 DICE Therapeutics, Inc. (DICE) - … crystaldiskinfo percentageWebDec 31, 2024 · DICE. The Nasdaq Stock Market LLC ... We are initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. Our … crystal disk info on linuxWebMar 30, 2024 · Posted by ABMN Staff on Mar 30th, 2024. DICE Therapeutics, Inc. ( NASDAQ:DICE – Get Rating) Director Ra Capital Management, L.P. purchased 155,089 shares of the company’s stock in a transaction that occurred on Thursday, March 23rd. The shares were purchased at an average cost of $26.67 per share, with a total value of … crystal disk info percentage usedWebPioneers in small molecule drug development. Our mission is to become an industry leader in creating transformative small molecule medicines for autoimmune and inflammatory … crystal disk info opisWebSep 30, 2024 · false Q3--12-31 0001645569 P2Y P2M P4Y P6Y1M6D P6Y1M6D P5Y6M P6Y1M6D P5Y6M P6Y1M6D 0.75 0.80 0.0074 0.0074 0.0042 0.0082 0.0110 0.0173 P9Y11M12D P9Y11M12D P5Y P6Y8M12D P5Y P6Y8M12 dwarf world games